Abstract:Experimental mouse models are indispensable for the preclinical development of cancer immunotherapies, whereby complex interactions in the tumor microenvironment (TME) can be somewhat replicated. Despite the availability of diverse models, their predictive capacity for clinical outcomes remains largely unknown, posing a hurdle in the translation from preclinical to clinical success. This study systematically reviews and meta-analyzes clinical trials of chimeric antigen receptor (CAR-) T cell monotherapies with their corresponding preclinical studies. Adhering to PRISMA guidelines, a comprehensive search of PubMed and ClinicalTrials.gov was conducted, identifying 422 clinical trials and 3157 preclinical studies. From these, 105 clinical trials and 180 preclinical studies, accounting for 44 and 131 distinct CAR constructs, respectively, were included. Patients' responses varied based on the target antigen, expectedly with higher efficacy and toxicity rates in hematological cancers. Preclinical data analysis revealed homogenous and antigen-independent efficacy rates. Our analysis revealed that only 4 % (n = 12) of mouse studies used syngeneic models, highlighting their scarcity in research. Three logistic regression models were trained on CAR structures, tumor entities, and experimental settings to predict treatment outcomes. While the logistic regression model accurately predicted clinical outcomes based on clinical or preclinical features (Macro F1 and AUC > 0.8), it failed in predicting preclinical outcomes from preclinical features (Macro F1 < 0.5, AUC < 0.6), indicating that preclinical studies may be influenced by experimental factors not accounted for in the model. These findings underscore the need for better understanding the experimental factors enhancing the predictive accuracy of mouse models in preclinical settings.

Syngeneic Mouse Models for Pre-Clinical Evaluation of CAR T Cells

Chimeric Antigen Receptor Natural Killer Cells: a Promising Antitumor Immunotherapy

Advancing CAR T-cell therapies: Preclinical insights and clinical translation for hematological malignancies

Advances and challenges of CAR T therapy and suitability of animal models (Review)

Predictive value of preclinical models for CAR-T cell therapy clinical trials: a systematic review and meta-analysis

Pre-Clinical Models for CAR T-Cell Therapy for Glioma

Perspectives on Chimeric Antigen Receptor T-Cell Immunotherapy for Solid Tumors

Mouse Tumor Models for Advanced Cancer Immunotherapy

Chimeric Antigen Receptor T Cells Applied to Solid Tumors

Advances and Hurdles in CAR T Cell Immune Therapy for Solid Tumors

Progress, implications, and challenges in using humanized immune system mice in CAR-T therapy-Application evaluation and improvement

Prospects for chimeric antigen receptor-modified T cell therapy for solid tumors

Chimeric Antigen Receptor T Cell Therapy: Challenges to Bench-to-Bedside Efficacy

Engineering enhanced chimeric antigen receptor-T cell therapy for solid tumors

Modeling Anti-Cd19 CAR T Cell Therapy in Humanized Mice with Human Immunity and Autologous Leukemia.

Recent Progress in Improving the Safety and Efficacy of Chimeric Antigen Receptor T Cell Therapy

Advances in promoting chimeric antigen receptor T cell trafficking and infiltration of solid tumors

Making Better Chimeric Antigen Receptors for Adoptive T-cell Therapy

Insight into next-generation CAR therapeutics: designing CAR T cells to improve clinical outcomes

Chimeric Antigen Receptor Immunotherapy for Solid Tumors: Choosing the Right Ingredients for the Perfect Recipe

Chimeric antigen receptor-immune cells against solid tumors: Structures, mechanisms, recent advances, and future developments